12:00 AM
Jul 28, 2008
 |  BC Week In Review  |  Company News  |  Deals

Arius, Roche deal

Roche will acquire antibody platform company Arius for about C$191 million (US$190.7 million) in cash. The deal includes the purchase of Arius’ common shares at C$2.44 and the purchase of issued and outstanding warrants at C$1.44-C$1.78. The per-share price is a 15% premium to Arius’ close of C$2.13...

Read the full 220 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >